Clinical Data AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data BioSpaceThis year's American Academy of Neurology meeting included a presentation that could one day set a new treatment standard for myasthenia gravis.Clinical DataNeuroscienceRead full story pharminent April 23, 2026 (Last updated: April 23, 2026) BioSpace This year’s American Academy of Neurology meeting included a presentation that could one day set a new treatment standard for myasthenia gravis. Clinical DataNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated CareNext: Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’ Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
